This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
and you are
over 18
years old
This is an observational trial.
You are contributing to medical knowledge about your condition.
Show me locations

The purpose

The frequency of neurological and psychiatric complaints for participants taking rilpivirine, elvitegravir, or dolutegravir reaches on average 20—30% during clinical trials. The inclusion and exclusion criteria for enrolling people living with HIV are at times so selective and the subsequent descriptions of minor or severe adverse events (AE's) so often imprecise and ambiguous that one cannot extrapolate these particular research results to practicing medicine. These adverse events negatively affect the patient's quality of life and ultimately his or her good adherence to treatments. This study aims at assessing the prevalence and at describing the neurological and psychiatric adverse events related to these drugs.

Provided treatments

  • Drug: prescription of at least one of the following drugs: rilpivirine, elvitegravir, dolutegravir

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02882230. The sponsor of the trial is Fondation Ophtalmologique Adolphe de Rothschild and it is looking for 1 volunteers for the current phase.
Official trial title:
Prospective Evaluation of Neurologic and Psychiatric Adverse Events of Rilpivirine, Elvitegravir, or Dolutegravir in a Real Life Setting